Because activated T cells were previously shown t o induce proliferation of human normal B-cell precursors (BCP) via the CD40 pathway, we investigated the effects of T cells on leukemic blasts isolated from patients with B-lineage acute lymphoblastic leukemia (BCP-ALL). An anti-CD3 activated human CD4+ T-cell clone was found t o induce significant cell proliferation in four of nine BCP-ALL samples analyzed. In one of these cases, the T-cell effect was clearly dependent on interaction between CD40 and its ligand. Accordingly, a more thorough analysis was performed on this particular leukemia (case 461, adult early pre-B-ALL, mBCR', Philadelphia+, i(9q)+). Thus, autologous CD4+ T cells isolated from the patient were also able t o induce CD40-dependent proliferation of the leukemic blasts. Analysis of the phenotype after coculture showed that, among UMAN B LYMPHOPOIESIS occurs in the liver during the first weeks of fetal life, whereupon the bone marrow becomes the site at which B-cell precursors (BCP) proliferate and differentiate to mature B cells. B-cell ontogeny requires a particular microenvironment that includes various accessory cells and cytokines."' Among accessory cells, stromal cells display a well-established supportive function for BCP This role can be mediated by stromal membrane molecules, such as CD44, VCAM1, and BST-1,9"3 or by secreted cytokines such as interleukin-7 (IL-7).6*14-16
the CD19+ cells, a proportion gradually lost expression of CD10 and CD34, whereas some cells acquired CD23. In addition, and in contrast with normal BCP, activated T cells promoted maturation of a subset of the case 461 leukemic cells into surface IgM' cells. The leukemic origin of the cycling and the maturing cells was assessed by the presence of i(9q), a chromosomal abnormality associated with this leukemia and evidenced by fluorescence in situ hybridization. Taken together, these results show that leukemic BCP can be activated via CD40 but that not all cases display detectable stimulation in response t o T cells despite their expression of CD40. In addition, the present data suggest that CD4' T cells could potentially play a role in the physiology of BCP-ALL. important. Thus, we have previously shown that T cells induce proliferation of normal BCP via the CD40-CD40 ligand interaction but do not promote differentiation into sIg+ B cells. '" During the process of B lymphopoiesis, aberrant genetic events may result in B-lineage acute lymphoblastic leukemia (ALL), which represents BCP that fail to undergo maturat i~n . ~~ In vitro studies have shown that cytokines, which include T-cell factors, affect proliferation of BCP-ALL cells.32 Thus, IL-4 and IL-13 have been described to inhibit cell pr~liferation'~~~~.'~ and to induce a p o p t~s i s ,~~ whereas IL-3 was shown to induce pr~liferation.'~ Although bone marrow stromal cells have been shown to prevent BCP-ALL cell death,3s,36 the question has not been addressed as to whether T cells can interact with the leukemic cells. This may appear of particular relevance because many cases of BCP-ALL bear surface-membrane CD40'7,'* and a ligand for CD40 is induced on T cells after a~tivation.'~ In this context, we evaluated the in vitro effects of T cells on leukemic human B lymphopoiesis. Activated T cells were observed to induce proliferation in some of the cases of BCP-ALL examined. One of the four T-cell-responsive cases (early pre-B ALL) was shown to clearly proliferate via the CD40 pathway, and further displayed a change of phenotype associated with cell maturation. These data show that T cells have a regulatory potential for BCP-ALL cells, which can be exerted through interaction of CD40 with its ligand. 
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" " " " " " " Double fluorescence analysis of cellular DNA and cell membrane antigen expression was performed by staining with the DNA-specific dye Hoechst 33342 (Calbiochem-Novabiochem. La Jolla, CA), followed by surface antigen labeling, as previously described.'6 Analysis and cell-sorting were performed on a FACStaf""' flow cytometer (Becton Dickinson).
FISH. FISH was performed according to a previously described method'.' on cytospin preparations from FACS-sorted cells. For the detection of isochromosome 9q i(9q) on methaphasic and interphasic cells. a classical satellite chromosome 9 probe (D9Z1) specific for the pencentric heterochromatin of chromosome 9 and biotin-labeled was used (Oncor, Gaithersburg, MD). Hybridization was revealed by Texas red avidin D (Vector Labs, Burlingame, CA). Two hundred cells were scored by two independent observers for the presence of i(9q).
RESULTS

Activated CD4' T cells induce BCP-ALL proliferation.
Because anti-CD3 activated CD4' T cells induce proliferation of normal BCPs isolated from fetal bone marrow;"' we investigated the effects of T cells on the proliferation of malignant BCP isolated from ALL patients. Leukemic blasts (CD19', sIg-) were isolated from the bone marrow or peripheral blood of pediatric and adult patients and the characteristics of the cells are reported in Table I . The BCP-ALL cells were cocultured for 5 days with irradiated anti-CD3 activated T-cell clone MT9. As shown in Table 1 , cells from four of the cases analyzed (461, 491, JOL, and VIT) displayed a significant increase in ['H] TdR incorporation in the presence of activated MT9 cells as compared with background. The responsive cases appeared heterogenous, both in terms of origin and of phenotype as judged by expression of CDIO, CD34, and CD40. Finally, heterogeneity was also observed in relation to karyotype because three of the five adult cases were Philadelphia-positive ALL (410, 461, and 523) and two of them had a monosomy 9p (410 and 461). (Fig l ) . In contrast to the results listed above, T-cell-dependent proliferation of BCP-ALL JOL cells appeared to be independent of the CD40 pathway (Fig l) , although this BCP-ALL expressed CD40.
Because proliferation of BCP-ALL cells from patient 461 (BCP-ALL 461 ) appeared to be mediated by a CD40-CD40 ligand interaction, a more extensive analysis was performed on these cells. As shown in Fig 2, anti-CD40 MoAb inhibited the ['H] TdR incorporation induced by activated MT9 T cells in a dose-dependent manner, with a maximal effect (-70%) at 78 ng/mL and half-maximal activity at approximately 30 ng/mL.
Next, it appeared to be of interest to evaluate the activity of autologous T cells. Thus, we tested the effect of a CD4' T-cell line (T-ALL 461 ) derived from patient 461 on proliferation of BCP-ALL 461 cells. As shown in Table 2 , similar levels of ['H] TdR incorporation were observed when BCP-ALL 461 cells were cocultured with anti-CD3-stimulated T-ALL 461 or MT9 T cells. In addition, the proliferation induced by the autologous T-ALL 461 cells was strongly dependent on a CD40-CD40 ligand interaction, as shown by the inhibition of proliferation when the coculture was performed in the presence of MoAb 89 (Table 2) .
Taken together, these results show that anti-CD3-stimulated CD4' T cells can induce CD40-dependent proliferation of purified BCP-ALL cells and that this effect can be reproduced with autologous CD4' T cells of patient origin.
The cycling cells in CD40-dependent cultrtres are leukemic R-lineage cells. Next, we further ascertained the nature of the proliferating cells recovered from coculture of T cells with BCP-ALL 461, which resulted in CD40-dependent proliferation. Thus, analysis of DNA content was performed after coculture with anti-CD3-activated MT9 cells. As shown in Fig 3, 24% to 26% of cells were found to be in S and G2/M phases of the cell cycle after 6 days of culture. Virtually all cycling cells expressed the CD I9 antigen, confirming their B-lineage affiliation (Fig 3) .
To formally show that the proliferating cells in coculture are leukemic cells and not normal B-lineage cells that can proliferate in response to activated T cells, a cytogenetic analysis was performed. Thus, cycling cells (S and GJM, high Hoechst content in Fig 3) were FACS-sorted after coculture, and the presence of the i(9q) chromosomal abnormality, which is constituted by two entire long arms (4) of one chromosome 9 and containing two adjacent pericentric heterochromatin regions, was determined by FISH on interphase cells. As shown in Fig 4 and in Table 3 , the i(9q), which could be detected in 87% of the cells as double-sized fluorescent signal before culture, was observed in 77% of the cycling cells after coculture with activated MT9 T cells. Finally, cocultures performed in the presence of anti-CD40 MoAb resulted in virtually no viable cells (data not shown). These data show the leukemic nature of the CD40-dependent proliferating BCP-ALL 461 cells.
RCP-ALL cells undergo maturation during CD40-dependent development. To further characterize the cells in CD40-dependent BCP-ALL cultures, a more extensive phenotypic analysis was performed. In a representative experiment (Fig 5) in which BCP-ALL 461 cells were cultured with irradiated anti-CD3 activated MT9 T cells, the majority (Fig 5) . The sIgM+ cells included both K and A light chains (Fig 5) . However, no sIgG+ cells were detected after coculture (Fig  5) , excluding potential activation of polyclonal normal B cells. Similar results were obtained in cocultures performed with activated CD4+ autologous T cells (data not shown).
As shown in Fig 6, analysis of the kinetics of coculture of BCP-ALL 461 with the activated MT9 T cells showed that, after 5 days, the CDlO+/CD34+ cells no longer represented the totality of CD19+ cells. Moreover, at this time, a subset of cells that expressed cytoplasmic p (cp) chain appeared (Fig 6) .
Finally, cell cycle analysis showed that a relatively high proportion (38%) of the cp+ cells were found in S+G,/M phases of cell cycle, consistent with the observation that a substantial percentage of the cycling CD19' cells did not express CD10/CD34 (data not shown).
To formally prove that the mature cells indeed represent the leukemic cells and not the emergence of normal cells, FISH analysis was performed. Thus, after 6 days of coculture with irradiated activated MT9 cells or autologous CD4+ T cells, sIgM+ cells were FACS-sorted and the presence of the i(9q) chromosomal abnormality was determined. As shown in Table 3 , the i(9q) abnormality could be detected in the majority of the sIgM+ cells, confirming the leukemic nature of the differentiated cells.
Taken together, these data show that CD40-dependent cocultures with stimulated CD4+ T cells can induce the maturation of BCP-ALL cells, as represented by the loss of the CDlO and CD34 antigens and the appearance of p chain expression.
DISCUSSION
The present report shows that anti-CD3 activated T cells can induce the proliferation of leukemic BCP isolated from B-lineage ALL patients.
For The responsive cases were found to represent only a proportion (4/9) of the samples tested. This result should be viewed in light of the intrinsic heterogeneity of B-lineage-ALL, a disease that includes a broad spectrum of BCP maturation stages with a significantly different phenotype.
In agreement with previous st~dies,~',~* the majority of the BCP-ALL cases presently examined were CD40+. In this context, we further showed that BCP-ALL cells can be induced to proliferate via the CD40 pathway in response to activated T cells. This finding represents the first description of functional activity for CD40 on leukemic BCP. However, again, heterogeneity was observed, because only one case (early pre-B, BCP-ALL 461) clearly responded in a CD40-dependent fashion among a total of seven cases bearing detectable CD40. The reason underlying the limited (case 491) or lack of detectable involvement of the CD40 pathway probably reflects the contribution of other T-cell factors for which only some of the leukemias bear receptors, resulting in either CD40-independent stimulation or delivery of a growth-antagonistic signal. However, the T-cell factors IL-3, IL-4, and IL-10 did not affect the proliferation of BCP-ALL 461 cells, as indicated by the use of neutralizing antibodies or of exogenous cytokines (data not shown).
Interaction of CD40 with its ligand or with an anti-CD40 MoAb presented by CD32 (FcyRII) transfected murine L cells (CD40 system) induces the proliferation of normal BCP.26.30+"' In a previous study, leukemic BCP were found not to respond to soluble anti-CD40 or to cross-linked MoAb on pla~tic.~' However, retrospectively, the above conditions appear to be suboptimal, because they do not permit the proliferation of normal BCP38 (unpublished observations). We addressed whether CD40 ligand provides a sufficient signal for proliferation in the absence of T cells. Neither cross-linked CD40 ligand nor CD40 ligand-positive L-cell transfectants were found to induce significant proliferation of BCP-ALL 461 (data not shown), raising the possibility of an additional T-cell factor requirement for CD4O-dependent proliferation.
Because two of the BCP-ALL tested (cases 461 and 410) displayed the same early pre-B phenotype (CDlO+, CD34', CD40', cy-) but did not respond identically, it does not appear that a given phenotype is associated with the capacity to respond to activated T cells via a CD40-CD40 ligand interaction. In addition, any association with a cytogenetic character, such as a Philadelphia chromosome that is found in a high proportion of B-lineage adult ALL4".'"' and diagnosed in three of the five cases of adult BCP-ALL tested (410, 461, and 523), could not be observed. The BCP-ALL case (461) that was found to respond via CD40 displayed an i(9q) chromosomal abnormality that is found both as a primary and as secondary aberration in slightly more than 2% of ALL cases,' ' ' resulting in a monosomy 9p and a trisomy 9q. Nethertheless, it would appear premature, however, to speculate that the i(9q) abnormality may in some way influence the response of the leukemic cells to CD40 stimulation.
Cell cycle analysis of BCP-ALL 461 showed that virtually all proliferating cells were B-lineage cells and that the cycling cells displayed an i(9q) chromosomal abnormality. These data formally confirm that the responsive cells are leukemic in nature and do not represent the expansion of potential contaminant normal cells in the cultures. This latter possibility, which appeared remote in view of the extremely low frequency of putative normal cells after purification of leukemic cells (below detection limits by FACS-analysis), nevertheless had to be excluded. The fact that the observed percentage of i(9q)' cells does not match 100% is a consequence of technical limitations in visually scoring positivity. Indeed, due to the spheric conformation of the nuclei and the cylindric conformation of i(9q) fluorescent signals, some specific i(9q) events do not appear as double-sized signals.
Our data further indicate a heterogenous phenotype of cultured cells, in contrast with the homogenous early pre-B phenotype of BCP-ALL 461 before coculture, with both immature CD19', CDIO'/CD34' and more mature CD19', CDIO-/CD34-and CD19', cy' cells being induced to proliferate in response to T cells. Maturation of the BCP-ALL 461 cells was confirmed by a more complete phenotype and by kinetic studies. Thus, the CD10 surface-membrane metallopeptidase was downregulated, as in normal BCP cocultured with activated T cells or in the CD40 A similar downregulation was observed with the progenitor cell marker CD34. Disappearance of these two markers was consistent with a maturation into sIgM' cells, which was shown by the appearance of y chain in the cytoplasm and at the cell surface after the loss of CD10 and CD34. The sIgM' subset cannot be accounted for by expansion of potential contaminant polyclonal normal B cells, which would have been expected to express sIgG on a substantial proportion of the population. Accordingly, the sIgM' cells were found to represent leukemic cells bearing the i(9q) chromosomal abnormality.
Taken together, these data indicate that T cells, including autologous CD4' T cells, have the potential to induce a differentiation sequence in BCP-ALL, as exemplified by release of a maturation block from early pre-B to sIgM' in BCP-ALL 461 cells. However, evaluation of the actual role of the CD40 pathway will require further studies. An active role in BCP-ALL differentiation would be supported by the observation that CD23 expression is induced in the leukemic cells, a feature shared with CD40-stimulation of normal BCP.2h.3n However, such a role for CD40 could not be shown, because coculture with activated T cells in the presence of anti-CD40 did not allow generation of sufficient cells to perform phenotypic analysis. Alternatively, T cells may only favor survival and proliferation of BCP-ALL cells through the CD40 pathway, thus permitting the action of T-cell factors that favor maturation. Thus, CD40-independent maturation may explain the fact that patients with X-linked hyperIgM syndrome characterized by a deficient CD40 ligand have mature B
Our results indicate that the apparent maturation block is not necessarily inherent to the leukemic cells and suggest the possibility that the lack of differentiation in BCP-ALL could be explained by an incapacity of the patients CD4' T cells to induce maturation in vivo. Along this scheme, it would be interesting to determine whether BCP-ALL patients may suffer from improper in vivo T cell-activation as a consequence of the disease. In addition, it may be of interest to investigate whether another cell type may block the induction of BCP-ALL maturation by CD4' T cells.
Finally, the observation that T-cell-dependent differentiation was seen in a case of leukemic BCP but has not been observed with normal BCP may suggest that the responsive leukemic cells represent the expansion of a particular maturation stage primed in vivo for acquisition of IgM in response to T cells. Thus, as normal BCP represent a continuum of maturation stages, only a small minority of cells would be For personal use only. on April 15, 2017. by guest www.bloodjournal.org From expected to have received the signal allowing T-dependent maturation, a proportion less than the current technical capacity for detection.
In keeping with these considerations, it would appear to be of interest to investigate the in situ localization of the bone marrow cells and factors that constitute the microenvironment of each step of leukemic versus normal BCP development.
